Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 4
2006 1
2007 1
2008 2
2009 1
2010 4
2011 8
2012 9
2013 8
2014 5
2015 9
2016 7
2017 9
2018 10
2019 11
2020 15
2021 11
2022 11
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
George DJ, Agarwal N, Ramaswamy K, Klaassen Z, Bitting RL, Russell D, Sandin R, Emir B, Yang H, Song W, Lin Y, Hong A, Gao W, Freedland SJ. George DJ, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2024 Apr 2. doi: 10.1038/s41391-024-00815-1. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38565911
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ. George DJ, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2024 Mar 27. doi: 10.1038/s41391-024-00816-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38538879
Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?
Freedland SJ, Ramaswamy K, Huang A, Sandin R, Schultz NM, Janjan N, George DJ. Freedland SJ, et al. Among authors: ramaswamy k. Future Oncol. 2023 Oct;19(31):2075-2082. doi: 10.2217/fon-2023-0354. Epub 2023 Aug 30. Future Oncol. 2023. PMID: 37646326 Free article. Review.
Multiscale stiffness of human emphysematous precision cut lung slices.
Kim JH, Schaible N, Hall JK, Bartolák-Suki E, Deng Y, Herrmann J, Sonnenberg A, Behrsing HP, Lutchen KR, Krishnan R, Suki B. Kim JH, et al. Among authors: krishnan r. Sci Adv. 2023 May 19;9(20):eadf2535. doi: 10.1126/sciadv.adf2535. Epub 2023 May 19. Sci Adv. 2023. PMID: 37205750 Free PMC article.
Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.
Freedland SJ, Hong A, El-Chaar N, Murty S, Ramaswamy K, Coutinho AD, Nimke D, Morgans AK. Freedland SJ, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2023 Sep;26(3):523-530. doi: 10.1038/s41391-022-00622-6. Epub 2022 Dec 14. Prostate Cancer Prostatic Dis. 2023. PMID: 36517634 Free PMC article.
118 results